A Phase II Study of Adjuvant S-1/Cisplatin Chemotherapy Followed by S-1-based Chemoradiotherapy in Advanced Gastric Cancer
Surgery is the only possible curative treatment of gastric cancer. However, the high
recurrence rate makes gastric cancer a disease difficult to cure by surgery alone. Despite
the benefit of CRT on local recurrence, the distant recurrence is the leading pattern of
failure. We hypothesized that gastric cancer outcome could be improved using a more
effective chemotherapy regimen. This study was conducted to evaluate the clinical outcomes
and toxicity of adjuvant treatment including S-1/cisplatin chemotherapy followed by S-1
based CRT.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease free survival
3 years
No
Sang-Hee Cho, M.D.Ph.D.
Principal Investigator
CNUHH
Korea: Institutional Review Board
CNUHH-MO-03
NCT01824004
April 2009
June 2012
Name | Location |
---|